SU2C Dream TeamTargeting the PI3K Pathway In Women's Cancers
Enroll in Clinical Trials Essential Information Headlines Meet the Dream Team
Our Clinical Trials

AACR-SU2C Clinical Trials Finder

The American Association for Cancer Research (AACR) and Stand Up To Cancer (SU2C) encourage you to use the AACR-SU2C Clinical Trials Finder, a free and confidential cancer clinical trial matching and referral service. [ Learn More ]

 


 

Breast Cancer

Triple Negative (Basal-like) Metastatic

NCT01623349 - Phase I of BKM120/Olaparib for Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

SU2C PI:  Ursula Matulonis, MD

Lead Site: Dana-Farber Cancer Institute
info@pi3k.org

ER/PR+MBC
NCT01791478 - Phase Ib BYL719 in combination with Letrozole
SU2C PI: Ingrid Mayer, MD
Lead Site: Vanderbilt-Ingram Cancer Center
info@pi3k.org

Stage II/III ER/PR

TBD - Phase II neo-adjuvant BKM120, BYL719, or placebo in combination with Letrozole
SU2C PI: Ingrid Mayer, MD
Lead Site: Vanderbilt-Ingram Cancer Center

Clinical Trial with Global sites for Patient Recruitment
info@pi3k.org

Triple Negative (Basal-like)

NCT01629615 - A Trial of BKM120 (a PI3K Inhibitor) in Patients with Triple Negative Breast Cancer

SU2C PI:  Jordi Rodon, MD (Europe)

SU2C PI:  Nancy Lin, MD (United States)

Lead Sites (Europe):  Vall d"Hebron Institute of Oncology - Barcelona

Lead Site (US):  Dana-Farber Cancer Institute

info@pi3k.org

HER2+
NCT01042925 - Phase I/II XL147/Herceptin or XL 147/Herceptin/Taxol
SU2C PI: Ian Krop, MD, PhD
Lead Site: Dana-Farber Cancer Institute
info@pi3k.org

AACR/SU2C Clinical Trials Finder

ER/PR+
NCT01082068 - Phase I/II XL147 or XL765 in combination with Letrozole
SU2C PI: Ian Krop, MD, PhD
Lead Site: Dana-Farber Cancer Institute
info@pi3k.org

AACR/SU2C Clinical Trials Finder

ER/PR+
NCT01248494 - Phase Ib, BEZ235 and BKM120 each in combination with Letrozole
SU2C PI: Ingrid Mayer, MD
Lead Site: Vanderbilt-Ingram Cancer Center
info@pi3k.org

All subtypes
NCT01277757 - Phase II MK-2206; PIK3CA mutation and/or PTEN loss
SU2C PI: Funda Meric-Bernstam, MD
Lead Site: MD Anderson Cancer Center
info@pi3k.org

All subtypes
NCT01263145 - Phase Ib, MK2206/Paclitaxel
SU2C PI: Ana Maria Gonzalez-Angulo, MD
Lead Site: MD Anderson Cancer Center
info@pi3k.org

 


 

Endometrial Cancer

Patients with recurrent or persistent endometrial cancer
TBD - Randomized Phase II Trametinib v. Trametinib plus GSK2141795
SU2C PI: Shannon Westin, MD, MPH
Lead Site: MD Anderson Cancer Center
info@pi3k.org

Patients with recurrent or persistent endometrial cancer
NCT01011933 - Phase II AZD6244
SU2C PI: Robert Coleman, MD
Lead Site: MD Anderson Cancer Center
info@pi3k.org

Patients with advanced or recurrent endometrial cancer
NCT00977574 - Phase II Taxol/Carboplatin/Bevacizumab vs. Taxol/Carboplatin/Temsirolimus vs. Ixabepilone/Carboplatin/Bevacizumab
SU2C PI: Carol Aghajanian, MD
Lead Site: Memorial Sloan-KetteringCancer Center
info@pi3k.org

PIK3CA mutation of recurrent advanced endometrial cancer

NCT01312753 - Phase II MK-2206

SU2C PI:  Andrea Myers, MD, PhD

Lead Site: Dana-Farber Cancer Institute
info@pi3k.org

AACR/SU2C Clinical Trials Finder

 

 

Ovarian Cancer

High Grade Serous

NCT01623349 - Phase I of BKM120/Olaparib for Triple Negative (Basal-like)Breast Cancer or High Grade Serous Ovarian Cancer

SU2C PI:  Ursula Matulonis, MD

Lead Site: Dana-Farber Cancer Institute
info@pi3k.org

Platinum-resistant PIK3CA or AKT mutation; PTEN loss by IHC

NCT01283035 - Phase II MK2206

SU2C PI:  Joyce F. Liu, MD, MPH

Lead Site:  Dana-Farber Cancer Insitute

info@pi3k.org

AACR/SU2C Clinical Trials Finder

 

HomeSitemapSearchContact
design by Digizyme ©2010 SU2C Dream Team
Targeting the PI3K Pathway in Women's Cancers
Stand Up To Cancer American Association for Cancer Research